HPC
RYTM icon

HM Payson & Co’s Rhythm Pharmaceuticals RYTM Stock Holding History

HM Payson & Co’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,701
Closed -$36K – 1156
2021
Q1 		$36K Buy
1,701
+1,188
+232% +$34.5K ﹤0.01% 667
2020
Q4 		$15K Buy
+513
New +$13K ﹤0.01% 827

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HM Payson & Co's RYTM Position: Q2 2021 in Review

HM Payson & Co sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2021, closing a stake of 1,701 shares — an estimated $36K sold.

HM Payson & Co first reported a position in RYTM in Q4 2020 and held it in 2 quarters. The position peaked at $36K in Q1 2021. 105 funds tracked by Wall St. Rank hold RYTM as of Q2 2021.

  • HM Payson & Co reported no remaining Rhythm Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 1,701 Rhythm Pharmaceuticals shares in Q2 2021, an estimated $36K.
  • HM Payson & Co first reported a position in Rhythm Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • HM Payson & Co's Rhythm Pharmaceuticals position peaked at $36K in Q1 2021.
  • 105 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.